p53 mutations in lung cancer associated with residential radon exposure

Citation
A. Yngveson et al., p53 mutations in lung cancer associated with residential radon exposure, CANC EPID B, 8(5), 1999, pp. 433-438
Citations number
43
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
ISSN journal
10559965 → ACNP
Volume
8
Issue
5
Year of publication
1999
Pages
433 - 438
Database
ISI
SICI code
1055-9965(199905)8:5<433:PMILCA>2.0.ZU;2-O
Abstract
Unusual mutation patterns in lung tumors among underground miners have been indicated, suggesting radon-specific alterations in the genome, but the da ta are not consistent. To investigate the association between residential r adon exposure and p53 mutations in lung tumors, we performed a study on cas es from a nationwide population-based investigation in Sweden, Our study in cluded 83 nonsmoking lung cancer cases and 250 smoking lung cancer cases, d iagnosed 1980-1984, with a time-weighted average radon exposure over 140 Bq /m(3) or up to 50 Bq/m(3). Radon was measured in dwellings occupied by the study subjects at some time since 1947, Information on smoking habits and o ther risk factors was obtained from questionnaires. After exclusions becaus e of the initiation of treatment or insufficient material, the p53-status o f 243 tumors was determined using PCR-single-stranded conformation polymorp hism analysis and sequencing determination of exons 5-8, The overall mutati on prevalence was 23.9%. An increased mutation prevalence was suggested amo ng those with high exposure to residential radon [odds ratio (OR), 1.4; 95% CI, 0.7-2.6], especially among nonsmokers (OR, 3.2; 95% CI, 0.7-15.5), but no specific mutational pattern was indicated. Furthermore, the mutation pr evalence seemed to be higher among smoking lung cancer cases than among non smoking cases (OR, 2.1; 95% CI, 0.9-5.0), and particularly among those smok ing less than 10 cigarettes per day. It may be concluded that residential e xposure to radon seems to contribute to a higher mutation prevalence of the p53 gene in lung tumors.